SAN DIEGO, June 20 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. will be presenting at the Piper Jaffray European Healthcare Conference on Friday, June 23, 2006 at 1:20 a.m. PT / 9:20 a.m. GMT in London, UK and at the William Blair Growth Stock Conference on Thursday, June 29, 2006 at 11:10 a.m. CT in Chicago, IL. Berthold Lensker, PhD, Executive Director, European Operations of Amylin Pharmaceuticals, will be presenting at the Piper Jaffray conference. Ginger L. Graham, Chief Executive Officer of Amylin Pharmaceuticals, will be providing a corporate overview at the William Blair conference.
The live presentations and breakout sessions will be webcast, and recordings will be made available following the events. The webcasts and recordings will be accessible through Amylin’s corporate website, located at www.amylin.com. To access the live webcasts, please log on to Amylin’s site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin’s research and development activities leverage the company’s expertise in metabolism to develop promising therapies to treat diabetes, obesity and cardiovascular disease. Amylin is located in San Diego, California with over 1200 employees nationwide. Further information on Amylin Pharmaceuticals is available at www.amylin.com.
Amylin Pharmaceuticals, Inc.
CONTACT: Alice Bahner, Executive Director, Investor Relations of AmylinPharmaceuticals, Inc., +1-858-552-2200, ext. 7272
Web site: http://www.amylin.com//
